Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Castelli

Showing results (31-40 of 64) with videos related to

Pageof 7
Sort By:
Haematologica|May 10, 2007
Lymphoproliferative disease and acquired C1 inhibitor deficiencyRoberto Castelli, Daniela Lambertenghi Deliliers, Lorenza C Zingale, et al.
Annals of Hematology|April 9, 2014
Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain functionRoberto Castelli, Giorgio Lambertenghi Deliliers, Riccardo Colombo, et al.
Journal of Thrombosis and Thrombolysis|October 13, 2017
High prevalence of heparin induced thrombocytopenia with thrombosis among patients with essential thrombocytemia carrying V617F mutationRoberto Castelli, Paolo Gallipoli, Riccardo Schiavon, et al.
Pharmaceuticals (Basel, Switzerland)|November 27, 2024
Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Heart Failure: An UpdateNicia I Profili, Roberto Castelli, Antonio Gidaro, et al.
Immunopharmacology and Immunotoxicology|January 3, 2012
Successful management with intravenous immunoglobulins in alemtuzumab-induced acute inflammatory demyelinating neuropathy: clinical report of three patientsRoberto Castelli, Giuseppe Gritti, Antonino Cannavò, et al.
Clinical Chemistry and Laboratory Medicine|January 27, 2016
Laboratory and clinical risk assessment to treat myelodysplatic syndromesAntonio Gidaro, Giorgio Lambertenghi Deliliers, Paolo Gallipoli, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 9, 2020
Does Outcome/Survival of Patients With Myelodysplastic Syndromes Should Be Predicted by Reduced Levels of ADAMTS-13? Results From a Pilot StudyRoberto Castelli, Luigi Bergamaschini, Thomas Teatini, et al.
British Journal of Haematology|January 6, 2016
High prevalence of splenic marginal zone lymphoma among patients with acquired C1 inhibitor deficiencyRoberto Castelli, Maddalena Alessandra Wu, Massimo Arquati, et al.
Journal of Clinical Medicine|November 13, 2021
Prothrombotic and Inflammatory Markers in Elderly Patients with Non-Alcoholic Hepatic Liver Disease before and after Weight Loss: A Pilot StudyAntonio Gidaro, Roberto Manetti, Alessandro Palmerio Delitala, et al.
Anti-Cancer Drugs|August 18, 2021
Risk-tailored treatment of splenic marginal zone lymphomaRoberto Castelli, Monica Balzarotti, Emanuele Salvi, et al.
Pageof 7

Showing results (31-40 of 64) with videos related to

Sort By:
Pageof 7
Haematologica|May 10, 2007
Lymphoproliferative disease and acquired C1 inhibitor deficiencyRoberto Castelli, Daniela Lambertenghi Deliliers, Lorenza C Zingale, et al.
Annals of Hematology|April 9, 2014
Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain functionRoberto Castelli, Giorgio Lambertenghi Deliliers, Riccardo Colombo, et al.
Journal of Thrombosis and Thrombolysis|October 13, 2017
High prevalence of heparin induced thrombocytopenia with thrombosis among patients with essential thrombocytemia carrying V617F mutationRoberto Castelli, Paolo Gallipoli, Riccardo Schiavon, et al.
Pharmaceuticals (Basel, Switzerland)|November 27, 2024
Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Heart Failure: An UpdateNicia I Profili, Roberto Castelli, Antonio Gidaro, et al.
Immunopharmacology and Immunotoxicology|January 3, 2012
Successful management with intravenous immunoglobulins in alemtuzumab-induced acute inflammatory demyelinating neuropathy: clinical report of three patientsRoberto Castelli, Giuseppe Gritti, Antonino Cannavò, et al.
Clinical Chemistry and Laboratory Medicine|January 27, 2016
Laboratory and clinical risk assessment to treat myelodysplatic syndromesAntonio Gidaro, Giorgio Lambertenghi Deliliers, Paolo Gallipoli, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 9, 2020
Does Outcome/Survival of Patients With Myelodysplastic Syndromes Should Be Predicted by Reduced Levels of ADAMTS-13? Results From a Pilot StudyRoberto Castelli, Luigi Bergamaschini, Thomas Teatini, et al.
British Journal of Haematology|January 6, 2016
High prevalence of splenic marginal zone lymphoma among patients with acquired C1 inhibitor deficiencyRoberto Castelli, Maddalena Alessandra Wu, Massimo Arquati, et al.
Journal of Clinical Medicine|November 13, 2021
Prothrombotic and Inflammatory Markers in Elderly Patients with Non-Alcoholic Hepatic Liver Disease before and after Weight Loss: A Pilot StudyAntonio Gidaro, Roberto Manetti, Alessandro Palmerio Delitala, et al.
Anti-Cancer Drugs|August 18, 2021
Risk-tailored treatment of splenic marginal zone lymphomaRoberto Castelli, Monica Balzarotti, Emanuele Salvi, et al.
Pageof 7